FDA approves Novartis Cosentyx biologic treatment option for hidradenitis suppurativa

 

• FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21

• As the only IL-17A inhibitor approved for HS, Cosentyx offers a meaningful new treatment option that demonstrated reductions in inflammatory nodules and abscesses, and flares2

• HS is a chronic, progressive and often painful disease that may affect 1 in 100 people worldwide

https://finance.yahoo.com/news/fda-approves-novartis-cosentyx-first-205000647.html